TY  - JOUR

T1  - Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.

JO  - Rheumatology (Oxford)

PY  - 2008/02/01

AU  - Wailoo A

AU  - Bansback N

AU  - Chilcott J

ED  - 

DO  - DOI: 10.1093/rheumatology/kem294

VL  - 47

IS  - 2

SP  - 119

EP  - 120

Y2  - 2024/12/22

ER  -